Last reviewed · How we verify
Biological: mRNA-1273
mRNA-based vaccine that encodes for the SARS-CoV-2 spike protein
mRNA-based vaccine that encodes for the SARS-CoV-2 spike protein Used for COVID-19 prevention.
At a glance
| Generic name | Biological: mRNA-1273 |
|---|---|
| Sponsor | ModernaTX, Inc. |
| Drug class | mRNA vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
This vaccine works by instructing cells to produce the SARS-CoV-2 spike protein, which triggers an immune response without causing the disease.
Approved indications
- COVID-19 prevention
Common side effects
- Pain at injection site
- Fatigue
- Headache
Key clinical trials
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction (PHASE4)
- COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose
- Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 (PHASE4)
- A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) (PHASE4)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076) (PHASE3)
- COVID Protection After Transplant-Immunosuppression Reduction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biological: mRNA-1273 CI brief — competitive landscape report
- Biological: mRNA-1273 updates RSS · CI watch RSS
- ModernaTX, Inc. portfolio CI